Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a tiny artery block stop a common brain bleed from coming back?

NCT ID NCT07806552

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This trial tests whether a minimally invasive procedure called middle meningeal artery embolization can prevent chronic subdural hematoma from recurring. Chronic subdural hematoma is a collection of blood on the brain's surface that often requires surgery to drain, but can come back. The procedure blocks blood flow to the artery feeding the bleed, which may stop rebleeding. Researchers will compare outcomes in 35 patients, measuring recurrence, need for repeat surgery, functional recovery, and hospital stay.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
middle meningeal artery embolization, a minimally invasive procedure that blocks blood flow to the middle meningeal artery to prevent recurrent bleeding
What this could lead to
If it works, this procedure could reduce the need for repeat surgery and speed recovery for people with chronic subdural hematoma.
What could go wrong
This is a small, early-stage trial, and the procedure carries risks such as bleeding, infection, or damage to nearby blood vessels. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Any age. 2. Radiologically confirmed chronic subdural hematoma (CSDH) on CT or MRI either Unilateral or Bilateral CSDH. 3. Patients considered suitable for standard surgical treatment of CSDH. 4. First presentation or recurrent CSDH requiring treatment. Exclusion Criteria: 1. Acute subdural hematoma or acute-on-chronic SDH where the acute component is the primary pathology. 2. Acute and severe neurological deterioration. 3. Subdural hematomas secondary to: * Intracranial tumors. * Intracranial infections. 4. Contraindications to angiography or embolization (for the MMAE group), such as: * Severe contrast allergy. * Untreatable coagulopathy. * Severe renal failure precluding contrast administration 5. Severe tortuosity or anatomical variations of the external carotid artery/MMA making catheterization unfeasible.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic subdural hematomas are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hematoma, Subdural, Chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic subdural hematomas Middle meningeal artery embolization

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.